Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

RQ Biotechnology

Request full access

Monoclonal antibodies for passive immunization against viruses

London, United KingdomFounded 2021Biotech & Life Sciences

About RQ Biotechnology

RQ Biotechnology Ltd. is a UK-based biotechnology company established in 2021 that specializes in discovering and developing potent, broad-spectrum monoclonal antibodies (mAbs) to provide passive immunity against viral infectious diseases. The company targets vulnerable populations, such as the immunocompromised, the elderly, and newborns, who cannot mount an effective response to traditional vaccines.

The company's scientific approach is inspired by the 'Red Queen' hypothesis, which posits that species must constantly evolve to survive against ever-evolving opposing species. RQ Bio applies this concept to the arms race between viruses and the human immune system, aiming to develop evolutionarily advanced antibodies. Its process involves using knowledge of virus evolution to select appropriate viral proteins for immunization, discovering the most potent and resilient natural human antibodies, and using its expertise in neutralization assays to select the best leads.

RQ Bio was co-founded by a team of scientific experts, including Mike Westby, Paul Kellam, and Jane Osbourn, who were previously involved with the UK BIA Antibody Taskforce. The company launched from stealth mode in May 2022. Its business model focuses on early-stage discovery and subsequent partnership with large pharmaceutical companies for clinical development, manufacturing, and commercialization. A key milestone was a licensing deal with AstraZeneca for its portfolio of mAbs against SARS-CoV-2, which included potential payments of up to $157 million plus royalties. The company also has a strategic collaboration with AbCellera to identify clinical candidates for targets including influenza and cytomegalovirus (CMV).

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
78.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Spinout, Woman Founder, DT and LS, uk is8 life sciences, UKSU, UKSU2010
Business model
Manufacturing
Client focus
B2B

Open roles

2 open roles
RoleTeamLocationPosted
Principal ScientistEngineeringEngineeringLondon, UK1w ago
Clinical Operations Manager / Senior Clinical Operations Manager – Phase I/II A…ClinicalClinicalLondon, UK1mo ago
From job postings in the last four months. Careers page ↗More startups hiring →

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2026 $114M $454M Forbion Capital Partners · Oxford University Innovation · Frazier Life Sciences · Wellington Management ↗
SEEDOther financing Dec 2022 $1.9M $7.4M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

RQ Biotechnology website traffic

Latest recorded traffic for RQ Biotechnology is 3.2K monthly website visits, up 442.4% over the last three months. RQ Biotechnology's team grew 23.1% over the past year.

Latest monthly visits3.2K 3-month web change+442.4% 1-year team growth+23.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

RQ Biotechnology in the London ecosystem

Live from Dealroom

The RQ Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Frazier Life Sciences
  • Forbion Capital Partners
  • Oxford University Innovation
  • Wellington Management
  • EQT Life Sciences
  • LifeArc
  • Oxford Science Enterprises
  • Monograph Capital

Other known investors1 additional known investor

  • University of Oxford
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · London HQ
Book a demo for the full country breakdown

See RQ Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.